Simcere Pharmaceutical Group Ltd is a pharmaceutical company focused on the research, development, and commercialization of drugs. Its portfolio spans oncology, neurology, autoimmune diseases, cardiovascular conditions, and anti-infection therapies. Key marketed products include Endostar, ENWEIDA, ENZESHU, COSELA, Sanbexin, Xianlinda, and Leruiping. The company maintains an active pipeline with compounds such as SIM0500, SIM0508, SIM0505, SIM0686, SIM0609, Suvemcitug, and Zemprocitinib in various stages of clinical trials. Simcere operates in China and the United States, with several drugs holding Investigational New Drug approvals in both regions. The company collaborates with partners such as Roche for the global development of the tri-specific antibody SIM0660. Its products are included in national medical insurance catalogs and clinical practice guidelines.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Drug Manufacturers - General Homepage simcere.com
Sector Healthcare IR page —
Tags
oncology, neurology, autoimmune diseases, cardiovascular, anti-infection, antibody-drug conjugates, bispecific antibodies, small molecule inhibitors, clinical trials, innovative drugs, Endostar, ENWEIDA, ENZESHU, COSELA, Sanbexin, Xianlinda, Leruiping, QUVIVIQ, Suvemcitug, Zemprocitinib, Deulorlatinib, SIM0500, SIM0508, SIM0505, SIM0686, SIM0609, SIM0692, SIM0811, SIM0610, SIM0278, SIM0532, SIM0660, Jiangsu Simcere Medical Diagnostics Co. Ltd.
Press page —

Metrics

Valuation  
Market cap HK$ 26.88B
Market cap (USD) $ 3.426B
P/E 17.21
PEG 1.33
P/BV 2.41
P/S 2.62
P/OCF 8.30
P/FCF 19.84
Dividend yield 2.0%
Turnover / mcap 0.12%
Returns  
ROE 16.3%
ROI 12.8%
ROIC 14.9%
Profit margin 17.4%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 12.9%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 11.1%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 33.3%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Revenue 7.731B 6.635B 6.608B 6.319B 5B 4.509B 5.037B
Net profit 1.344B 733.165M 714.761M 932.768M 1.507B 669.534M 1.004B
Free cash flow 1.151B 615.556M -828.807M 676.094M — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019
Share price 9.74 5.6 6.17 9.84 8.4 — —
Price performance 12m 0.78 -0.08 -0.41 0.12 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Simcere Pharmaceutical Group Ltd (ticker 2096), listed in Hong Kong.

ETFs Holding Simcere Pharmaceutical Group Ltd

ETF Weight in ETF Shares Market value As of
AVEE 0.13% 127,000 $ 170.28K Nov 16, 2026
AVES 0.07% 804,000 $ 1.078M Nov 16, 2026
AVEM 0.04% 7,252,000 $ 9.723M Nov 16, 2026
DFSE 0.03% 119,000 $ 165.197K Nov 12, 2026
DFEM 0.01% 916,000 $ 1.272M Nov 12, 2026
DFAE 0.01% 803,000 $ 1.115M Nov 12, 2026
DFAX 0.01% 604,000 $ 838.477K Nov 12, 2026